Direct-Acting Agents for Hepatitis C Reduce Risk for Incident Diabetes
In a large cohort of patients with HCV, the use of DAA was associated with significantly lower incidence and risk for subsequent diabetes.
Hepatitis
Age, Race, and Genotype Associated With Hepatitis B Envelope Antigen Prevalence
Hepatitis B e antigen prevalence and other hepatitis B virus markers decline with age and differ by race with HBeAg persisting longer among Asian people.
Glecaprevir/Pibrentasvir Approved to Treat All 6 Genotypes of HCV in Pediatric Patients
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
Intersection of ID & OUD Epidemic: What ID Clinicians Should Know
The epidemic of opioid use disorder has led to substantial increases in new cases of HCV and HIV infection, as well as hospitalizations for other OUD-related infections.
Directly Observed Therapy Improves HCV Care in Opioid Agonist Programs
In onsite HCV care delivered to PWID in opioid agonist therapy programs, a greater adherence was associated with directly observed therapy when compared with self-administered individual treatment.
DAA Treatment Before Liver Transplantation May Improve Outcome
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
No Significant Effect on Maternal/Fetal Bone Mineral Density With Maternal TDF Use
There was no significant effect of maternal tenofovir use for the prevention of mother-to-child transmission of HBV on bone mineral density in either the mother or child 1 year after delivery.
Antiviral Therapy May Prevent Liver Injury in Hepatitis B/TB Co-Infection
Patients with TB and HBV co-infection should be given antiviral treatment for HBV when anti-TB therapy is initiated.
Occult Hepatitis B in Hepatitis C-Associated Hepatocellular Carcinoma
Occult hepatitis B virus infection was detected in 50% of patients with chronic hepatitis C with CHC-related hepatocellular carcinoma.
Benefits of Expanding HCV Treatment Outweigh Short-Term Costs for State Medicaid Programs
Findings suggest that states should consider revising their HCV treatment policies to include all individuals infected with HCV to achieve significant patient- and population-level benefits.
Next post in Hepatitis
